January 28th 2021
By Tony Hagen
In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.
January 27th 2021
The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.
January 7th 2021
Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.
December 8th 2020
A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.
November 30th 2020
The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach.
November 24th 2020
By Skylar Jeremias
Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.
November 21st 2020
By Bincy P. Abraham, MD
Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.
November 16th 2020
Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.
The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.
Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.
